Study of Photopheresis in the Treatment of Erythrodermic MF and SS
Status:
Withdrawn
Trial end date:
2026-06-01
Target enrollment:
Participant gender:
Summary
PROMPT: a study of photopheresis for the treatment of erythrodermic mycosis fungoides and
Sézary syndrome
For this study, the investigators invite patients suffering from erythrodermic mycosis
fungoides (MF) and Sézary syndrome (SS) whose skin symptoms have not responded to other types
of treatment prescribed by their doctors (symptoms came back or got worse) as well as
patients that never received any treatment.
Patients will be treated with photopheresis every two weeks for the first three months,
thereafter once monthly. One treatment cycle consists of 2 day treatment in a row. After 6
months of treatment, treatment can be given every 5 to 8 weeks.
During the photopheresis procedure, the patient's blood is collected into a specialized
machine (THERAKOS CELLEX) that separates the white blood cells from the other blood
components. The other blood components are returned to the patient and white blood cells are
then treated with the drug methoxsalen, which makes them sensitive to ultraviolet light. The
treated white blood cells are exposed to ultraviolet A (UVA) irradiation inside the machine,
and then returned to the patient.
As photopheresis has been used worldwide for more than 30 years, each hospital has developed
their own guidelines (e.g. which patients, frequency, etc). Recently, experts in the field
have developed a guidance which will now be tested in this study.
Phase:
Phase 2
Details
Lead Sponsor:
European Organisation for Research and Treatment of Cancer - EORTC